BYBlake Yarascavitch

Blake Yarascavitch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Blake Yarascavitch has a total of 140 co-authors. Here are the top co-authors by number of shared publications:

  • Forough Farrokhyar

    McMaster Pediatric Brain Tumor Study Group, McMaster University, Hamilton, Canada

    10 shared publications
  • Kesava Reddy

    Division of Neurosurgery, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

    6 shared publications
  • Branavan Manoranjan

    McMaster Pediatric Brain Tumor Study Group, McMaster University, Hamilton, Canada

    5 shared publications
  • Adam Fleming

    McMaster University

    4 shared publications
  • Arjuna Maharaj

    McMaster Pediatric Brain Tumor Study Group, McMaster University, Hamilton, Canada

    4 shared publications
  • Naresh Murty

    From the University of Toronto, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; and University of Texas Southwestern Medical Center, Dallas, Texas

    4 shared publications

Latest Publications

  • External ventricular drainage in the management of pediatric patients with posterior fossa tumors and hydrocephalus: a retrospective cohort study

    by Leonard H. Verhey, Arjuna Maharaj, Nikunj Patel, Branavan Manoranjan, Olufemi Ajani, Adam Fleming, Forough Farrokhyar, Sheila K. Singh, Blake Yarascavitch, on behalf the Pediatric Brain Tumor Study Group

    Purpose To determine whether intraoperative adjunctive EVD placement in patients with a posterior fossa tumor (PFT) led to improved surgical, radiographic, and clinical outcomes compared to those who did not receive an EVD. Methods Patients were grouped as those who underwent routine intraoperative adjunctive EVD insertion and those who did not at time of PFT resection. Patients who pre-operatively required a clinically indicated EVD insertion were excluded. Comparative analyses between both groups were conducted to evaluate clinical, radiological, and pathological outcomes. Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were computed for post-operative outcomes. Results Fifty-five selected patients were included, 15 who had an EVD placed at the time of PFT resection surgery, and 40 who did not. Children without an EVD did not experience a higher rate of complications or poorer post-operative outcomes compared to those with an EVD placed during resection surgery. There was no significant difference in the degree of gross total resection (p = 0.129), post-operative CSF leak (p = 1.000), and post-operative hemorrhage (p = 0.554) between those with an EVD and those without. The frequency of new cranial nerve deficits post-operatively was higher in those with an EVD (40%) compared to those without (3%, p = 0.001). There was a trend towards more frequently observed post-operative hydrocephalus in the EVD group (p = 0.057). Conclusion The routine use of EVD as an intraoperative adjunct in clinically stable pediatric patients with posterior fossa tumors and hydrocephalus may not be associated with improved radiological or clinical outcomes.


  • Predictive measures and outcomes of extent of resection in juvenile pilocytic astrocytoma

    by Arjuna Maharaj, Branavan Manoranjan, Leonard H. Verhey, Adam J. Fleming, Forough Farrokhyar, Saleh Almenawer, Sheila K. Singh, Blake Yarascavitch


  • Analysis of factors that influence neurosurgical length of hospital stay among newly diagnosed pediatric brain tumor patients

    by Muhammad Hasan, Dion Diep, Branavan Manoranjan, Arjuna Maharaj, Sabrina Chaudhry, Saqib Shaheen, Forough Farrokhyar, Adam J. Fleming, Olufemi Ajani, Sheila K. Singh, et al.

    Background: Postoperative length of stay (LOS) carries a high burden of healthcare costs. In resource‐intense specialties such as neurosurgery, it is imperative to identify factors that influence LOS to improve care. The current study investigates the potential for variables that affect clinical presentation, tumor characteristics, treatment modalities, and postoperative complications to impact overall LOS in pediatric brain tumor patients.Methods: A retrospective cohort study design was used with patients enrolled in the McMaster Pediatric Brain Tumor Study Group database. All patients up to 18 years of age, presenting with a newly diagnosed brain tumor admitted to and discharged from neurosurgery, were included. Patients were sorted into three cohorts: short LOS (≤3 days), extended LOS (≥20 days), and control LOS (4‐19 days).Results: Of the 124 patients included, 20 (65% male; median age: 9.1 years; range, 0.8‐17.4 years) were considered short LOS, 28 (61% male; median age: 4.7 years; range, 0.4‐14.7 years) were considered extended LOS, and 76 (57% male; median age: 8.5 years; range, 0.3–17.9 years) were considered control LOS. Variables that prolonged LOS were emesis at presentation (P < 0.001), developmental delay (P = 0.02), multiple surgeries (P = 0.004), tumor location (P < 0.05), subtotal resection (P = 0.02), feeding tube (P < 0.001), adjuvant chemoradiotherapy (P < 0.001), and posterior fossa syndrome (P = 0.004).Conclusions: This study identifies variables related to clinical presentation, tumor characteristics, treatment modalities, and postoperative complications associated with extended LOS. These findings uncover novel predictors of LOS that can be used to guide future research and improve health resource management.


  • Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience

    by Michelle M. Kameda-Smith, Alick Wang, Noora Abdulhadi, Rebecca Voth, Anjali Sergeant, Arjuna Maharaj, David Bakhshinyan, Ashley A. Adile, Akshat M. Pai, Olufemi Ajani, et al.

    Introduction: Children diagnosed with medulloblastoma (MB) who are refractory to upfront therapy or experience recurrence have very poor prognoses. Although phase I and phase II trials exist, these treatments bear significant treatment-related morbidity and mortality. Methods: A retrospective review of children diagnosed with a recurrence of MB from 2002 to 2015 at McMaster University was undertaken. Results: Recurrent disease in 10 patients involved leptomeningeal dissemination, with 3 experiencing local recurrence. In three recurrent patients the disease significantly progressed, and the children were palliated. The remaining 10 children underwent some form of salvage therapy, including surgical re-resection, radiation, and chemotherapy, either in isolation or in varying combinations. Of the 13 children experiencing treatment-refractory or recurrent disease, 4 are currently alive with a median follow-up of 38.5 months (75.5 months). Of the eight patients with molecular subgrouping data, none of the Wnt MB experienced recurrence. Conclusion: Recurrent MB carried a poor prognosis with a 5-year overall survival (OS) of 18.2% despite the administration of salvage therapy. The upfront therapy received, available treatment, and tolerability of the proposed salvage therapy resulted in significant heterogeneity in the treatment of our recurrent cohort. Traitement de sauvetage dans le cas du médulloblastome chez l’enfant : une expérience menée au sein d’un établissement hospitalier. Introduction: Les enfants chez qui l’on a diagnostiqué un médulloblastome réfractaire à un traitement initial ou qui sont victimes d’une récidive présentent d’habitude des pronostics de guérison vraiment défavorables. Bien qu’il existe des traitements basés sur des essais cliniques de phases I et II, ces traitements ont tendance à produire des taux notables de morbidité et de mortalité. Méthodes: Nous avons ainsi mené à l’Université McMaster une analyse rétrospective des dossiers d’enfants chez qui l’on avait diagnostiqué entre 2002 et 2015 une récidive de médulloblastome. Résultats: La réapparition de cette maladie chez 10 patients a provoqué un phénomène de diffusion leptoméningée, trois d’entre eux étant victimes d’une récidive locale. Sur ces 10 jeunes patients, la maladie a progressé de façon importante : ces enfants ont alors été transférés aux soins palliatifs. Quant aux autres 10 enfants, ils ont subi un certain type de traitement de sauvetage (des résections chirurgicales, de la radiothérapie, de la chimiothérapie), que ce soit de façon exclusive ou en variant les combinaisons possibles. Sur les 13 enfants réfractaires à un traitement initial ou victimes d’une récidive, 4 sont toujours en vie, leur suivi médian ayant été de 38,5 mois (75,5 mois). Sur les 8 patients pour qui on a pu obtenir des données moléculaires, aucun de ceux qui étaient atteints d’un médulloblastome du sous-type Wnt n’a connu de récidive. Conclusion: Les médulloblastomes qui réapparaissent après une période de guérison complète présentent un pronostic de guérison défavorable. Leur taux de survie globale est en effet de 18,2 % au cours d’une période de 5 ans, et ce, même après avoir bénéficié d’un traitement de sauvetage. Ajoutons aussi que le type de traitement initial reçu, la disponibilité des traitements ainsi que la tolérance à l’égard des traitements de sauvetage proposés a entraîné une grande hétérogénéité dans le traitement de ces jeunes patients victimes d’une récidive.


  • BMI1 is a therapeutic target in recurrent medulloblastoma

    by David Bakhshinyan, Chitra Venugopal, Ashley A. Adile, Neha Garg, Branavan Manoranjan, Robin Hallett, Xin Wang, Sujeivan Mahendram, Parvez Vora, Thusyanth Vijayakumar, et al.

    Medulloblastoma (MB) is the most frequent malignant pediatric brain tumor, representing 20% of newly diagnosed childhood central nervous system malignancies. Although advances in multimodal therapy yielded a 5-year survivorship of 80%, MB still accounts for the leading cause of childhood cancer mortality. In this work, we describe the epigenetic regulator BMI1 as a novel therapeutic target for the treatment of recurrent human Group 3 MB, a childhood brain tumor for which there is virtually no treatment option beyond palliation. Current clinical trials for recurrent MB patients based on genomic profiles of primary, treatment-naive tumors will provide limited clinical benefit since recurrent metastatic MBs are highly genetically divergent from their primary tumor. Using a small molecule inhibitor against BMI1, PTC-028, we were able to demonstrate complete ablation of self-renewal of MB stem cells in vitro. When administered to mice xenografted with patient tumors, we observed significant reduction in tumor burden in both local and metastatic compartments and subsequent increased survival, without neurotoxicity. Strikingly, serial in vivo re-transplantation assays demonstrated a marked reduction in tumor initiation ability of recurrent MB cells upon re-transplantation of PTC-028-treated cells into secondary recipient mouse brains. As Group 3 MB is often metastatic and uniformly fatal at recurrence, with no current or planned trials of targeted therapy, an efficacious targeted agent would be rapidly transitioned to clinical trials.


  • Analysis of surgical and MRI factors associated with cerebellar mutism

    by Anjali Sergeant, Michelle Masayo Kameda-Smith, Branavan Manoranjan, Brij Karmur, JoAnn Duckworth, Tina Petrelli, Katey Savage, Olufemi Ajani, Blake Yarascavitch, M. Constantine Samaan, et al.

    The surgical risk factors and neuro-imaging characteristics associated with cerebellar mutism (CM) remain unclear and require further investigation. Therefore, we aimed to examine surgical and MRI findings associated with CM in children following posterior fossa tumor resection. Using our data registry, we retrospectively collected data from pediatric patients who acquired CM and were matched based on age and pathology type with individuals who did not acquire CM after posterior fossa surgery. The strength of association between surgical and MRI variables and CM were examined using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). A total of 22 patients (11 with and 11 without CM) were included. Medulloblastoma was the most common pathology among CM patients (91%); the remaining 9% were diagnosed with a pilocytic astrocytoma. Tumor attachment to the floor of the fourth ventricle (OR 6; 95% CI 0.7–276), calcification/hemosiderin deposition (OR 7; 95% CI 0.9–315.5), and post-operative peri-ventricular ischemia on MRI (OR 5; 95% CI 0.5–236.5) were found to have the highest measures of association with CM. Our results may suggest that tumor attachment to the floor of the fourth ventricle, pathological calcification, and post-operative ischemia have a relatively higher prevalence in patients with CM. Collectively, our work calls for a larger multi-institutional cohort study of CM patients to encourage further investigation of the determinants and management of CM in order to potentially minimize its development and predict onset.


  • Top Cited Papers
    Open Access

    Endovascular Thrombectomy for Acute Ischemic Stroke

    by Jetan H. Badhiwala, Farshad Nassiri, Waleed Alhazzani, Magdy H. Selim, Forough Farrokhyar, Julian Spears, Abhaya V. Kulkarni, Sheila Singh, Abdulrahman Alqahtani, Bram Rochwerg, et al.

    Quiz Ref ID The current standard therapy for acute ischemic stroke is intravenous administration of tissue plasminogen activator (tPA).1 Although intravenous tPA improves survival and functional outcomes when administered as early as possible after onset of ischemic stroke,2 its use is limited by the narrow therapeutic time window (3 and by important contraindications, including coagulopathy, recent surgery, or stroke or head injury within the past 3 months.4 Ultimately, as few as 10% of patients presenting with ischemic stroke can be eligible for treatment with intravenous tPA.5 Moreover, intravenous fibrinolysis is associated with long recanalization times and poor revascularization rates in proximal large arterial occlusions, and the prognosis of these patients remains poor.6,7


  • Atlantoaxial instability in acute odontoid fractures is associated with nonunion and mortality

    by Nathan Evaniew, Blake Yarascavitch, Kim Madden, Michelle Ghert, Brian Drew, Mohit Bhandari, Desmond Kwok


  • Management of inadvertent injury to superior sagittal sinus in parasagittal meningioma: technical note

    by Aa Ahmed, B Yarascavitch, N Murty

    Background: Parasagittal meningioma is a common type of intracranial meningiomas. Surgical resection of such lesions can result in injury to superior sagittal sinus. In rare occasions, extended craniotomy might be required for uncontrollable hemorrhage from a lacerated venous wall. Objective: In order to avoid extended craniotomy, we attempted a surgical technique that would provide more sustained control over the lacerated venous sinus. Method: A 56 year old lady underwent surgical resection for parasagittal meningioma. The lateral wall of the superior sagittal sinus was preached while scraping the tumor capsule from the sinus wall. Owing to difficulty in controlling the bleeding site, a tack up falx-assisted tension suture was attempted with a mass of Gelfoam and Surgicel over the laceration. Results: Adequate control for the venous sinus laceration. Conclusion: The falx-assisted suturing technique is quick, easy to perform and efficient in maintaining a constant tamponade effect over the lacerated site. We highly recommend such technique prior to extending the craniotomy over an injured venous sinus.